Evidence map›Paper›PMID 36215479›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2022

Bip-Yorkie interaction determines oncogenic and tumor-suppressive roles of Ire1/Xbp1s activation.

Shuai Yang, Hua Jiang, Weixiang Bian, Wenyan Xu, Yifan Guo, Sha Song, Jiadong Zheng, Xiaoyu Kuang, Chenxi Wu, Xiang Ding and 7 more

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Vitamin B3 suppressesTranslational cancer research · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. SON-dependent nuclear speckle rehabilitation alleviates proteinopathies.bioRxiv : the preprint server for biology · 2025
    Article
  9. Article
  10. Article
  11. Frontiers in pharmacology · 2025
    Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Shuai YangCollege of Life Sciences, Zhejiang University, Hangzhou 310058, China.ORCID 0000-0002-1353-2941
Hua JiangWestlake Laboratory of Life Sciences and Biomedicine, Hangzhou 310024, China.
Weixiang BianWestlake Laboratory of Life Sciences and Biomedicine, Hangzhou 310024, China.
Wenyan XuKey Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou 310024, China.
Yifan GuoKey Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou 310024, China.ORCID 0000-0001-6551-2945
Sha SongKey Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou 310024, China.
Jiadong ZhengKey Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou 310024, China.ORCID 0000-0001-9530-1559
Xiaoyu KuangKey Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou 310024, China.
Chenxi WuCollege of Traditional Chinese Medicine, North China University of Science and Technology, Tangshan 063210, China.
Xiang DingShanghai Key Laboratory of Signaling and Diseases Research, School of Life Science and Technology, Tongji University, Shanghai 200092, China.
Xiaowei GuoSchool of Medicine, Hunan Normal University, Changsha 410013, China.ORCID 0000-0002-8707-7849
Lei XueShanghai Key Laboratory of Signaling and Diseases Research, School of Life Science and Technology, Tongji University, Shanghai 200092, China.
Zijing YuWestlake Laboratory of Life Sciences and Biomedicine, Hangzhou 310024, China.
Yongdeng ZhangWestlake Laboratory of Life Sciences and Biomedicine, Hangzhou 310024, China.
Hyung Don RyooDepartment of Cell Biology, New York University Grossman School of Medicine, New York, NY 10016.ORCID 0000-0002-1046-535X
Xu LiWestlake Laboratory of Life Sciences and Biomedicine, Hangzhou 310024, China.ORCID 0000-0002-9401-6382
Xianjue MaKey Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou 310024, China.ORCID 0000-0003-4360-3947
Westlake University · CNTongji University · CNHunan Normal University · CNNew York University · USNorth China University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unfolded protein response (UPR) is the mechanism by which cells control endoplasmic reticulum (ER) protein homeostasis. ER proteostasis is essential to adapt to cell proliferation and regeneration in development and tumorigenesis, but mechanisms linking UPR, growth control, and cancer progression remain unclear. Here, we report that the Ire1/Xbp1s pathway has surprisingly oncogenic and tumor-suppressive roles in a context-dependent manner. Activation of Ire1/Xbp1s up-regulates their downstream target Bip, which sequesters Yorkie (Yki), a Hippo pathway transducer, in the cytoplasm to restrict Yki transcriptional output. This regulation provides an endogenous defensive mechanism in organ size control, intestinal homeostasis, and regeneration. Unexpectedly,

Indexed as

Drosophila ProteinsProtein Serine-Threonine KinasesAnimalsCarcinogenesisDNA-Binding ProteinsDrosophilaEndoplasmic ReticulumEndoribonucleasesHippo Signaling PathwayHumansUnfolded Protein ResponseX-Box Binding Protein 1DNA-Binding ProteinsDrosophila ProteinsEndoribonucleasesERN1 protein, humanProtein Serine-Threonine KinasesX-Box Binding Protein 1Xbp1 protein, DrosophilaXBP1 protein, humanHippo signalingsize controltriple-negative breast cancertumorigenesisunfolded protein response

Identifiers

PMID36215479
PMCPMC9586321
OpenAlexW4304098293

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.